Unknown

Dataset Information

Engineering enhanced CAR T-cells for improved cancer therapy.


ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

SUBMITTER: Milone MC 

PROVIDER: S-EPMC8412433 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature